Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024.
López-Lacort M, Muñoz-Quiles C, Mira-Iglesias A, López-Labrador FX, Mengual-Chuliá B, Fernández-García C, Carballido-Fernández M, Pineda-Caplliure A, Mollar-Maseres J, Shalabi Benavent M, Sanz-Herrero F, Zornoza-Moreno M, Pérez-Martín JJ, Alfayate-Miguelez S, Pérez Crespo R, Bastida Sánchez E, Menasalvas-Ruiz AI, Téllez-González MC, Esquiva Soto S, Del Toro Saravia C, Sanz-Muñoz I, Eiros JM, Matías Del Pozo V, Toquero-Asensi M, Pastor-Villalba E, Lluch-Rodrigo JA, Díez-Domingo J, Orrico-Sánchez A.
López-Lacort M, et al. Among authors: munoz quiles c.
Euro Surveill. 2024 Feb;29(6):2400046. doi: 10.2807/1560-7917.ES.2024.29.6.2400046.
Euro Surveill. 2024.
PMID: 38333937
Free PMC article.